- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.05. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| LIXTE BIOTECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 12.05. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 18.04. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.04. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 04.04. | Lixte Biotechnology files to sell 467,393 shares of common stock by selling shareholders | 2 | Seeking Alpha | ||
| 04.04. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | 2 | SEC Filings | ||
| 31.03. | Lixte Biotechnology Holdings, Inc.: LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 | 1 | GlobeNewswire (USA) | ||
| 27.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.03. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer | 130 | GlobeNewswire (Europe) | -Started Two New Clinical Trials, Collaborating with MD Anderson and The Netherlands Cancer Institute for Treatment of Ovarian and Colorectal Cancer- -Received Exclusive Patent License Agreement with... ► Artikel lesen | |
| 24.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 10-K, Annual Report | 3 | SEC Filings | ||
| 11.03. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Adds Northwestern University's Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer | 1 | GlobeNewswire (USA) | ||
| 21.02. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 13.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Announces Closing of $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 1 | GlobeNewswire (USA) | ||
| 13.02. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 11.02. | LIXTE Biotechnology announces $1.05M registered direct offering; shares fall | 3 | Seeking Alpha | ||
| 11.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 2 | GlobeNewswire (USA) | ||
| 10.02. | Lixte Biotechnology Holdings, Inc.: LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement | 131 | GlobeNewswire (Europe) | PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced... ► Artikel lesen | |
| 06.01. | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.12.24 | LIXTE BIOTECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | - | SEC Filings |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 1,910 | 0,00 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| OCUGEN | 0,779 | +0,85 % | Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST-Modifier Gene Therapy for the Treatment of Stargardt Disease | MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| MAINZ BIOMED | 2,775 | -100,00 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekannt | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomed gibt Interim-Ergebnisse seiner klinischen Studie eAArly DETECT 2 bekannt
16.05.2025 /... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,800 | +0,63 % | Could Viking Therapeutics Become the Next Eli Lilly? | ||
| IMMUNITYBIO | 2,574 | +0,43 % | FDA grants expanded access to ImmunityBio's Anktiva for lymphopenia | ||
| MARINOMED BIOTECH | 17,000 | +1,49 % | EQS-PVR: Marinomed Biotech AG: Veröffentlichung gemäß § 135 Abs. 2 BörseG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Marinomed Biotech AG
Marinomed Biotech AG: Veröffentlichung gemäß § 135 Abs. 2 BörseG mit dem Ziel der europaweiten Verbreitung
04.06.2025 / 09:28... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,910 | 0,00 % | Was Jim Cramer Right About Recursion Pharmaceuticals, Inc. (RXRX)? | ||
| ORAGENICS | 3,560 | 0,00 % | Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split | SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company advancing innovative treatments for brain-related health conditions... ► Artikel lesen | |
| CAPRICOR | 11,040 | +2,22 % | Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer | SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced... ► Artikel lesen | |
| FIBROGEN | 0,258 | -0,12 % | FibroGen, Inc.: FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update | Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now... ► Artikel lesen | |
| REVIVE THERAPEUTICS | 0,008 | 0,00 % | Revive Therapeutics Ltd: Revive develops new bucillamine formulation | ||
| BIOLINERX | 3,283 | -100,00 % | BioLineRx Ltd: BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting | - 4 of 11 PDAC patients in the pilot phase remained progression free at over one year
- Poster presentation on Saturday, May 31 st
TEL AVIV, Israel, May 30, 2025... ► Artikel lesen | |
| RADIUS HEALTH | - | - | +850% CVR-Jackpot: Biotech-Tipp Radius Health beschert Anlegern Geldsegen | Der Optionsvoodoo-Chatraum von sharedealsPlus brummte letzte Woche vor Begeisterung, denn ein längst vergessener Trade sorgt für Jubelstürme und prall gefüllte Konten bei den Mitgliedern des Anlegerclubs... ► Artikel lesen | |
| MARKER THERAPEUTICS | 1,170 | -1,68 % | Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma | Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive... ► Artikel lesen | |
| COCRYSTAL | 1,470 | -0,68 % | Cocrystal Pharma, Inc. - 8-K, Current Report |
Das Unternehmen LIXTE BIOTECHNOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIXTE BIOTECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.